北京大学医学部机构知识库
Advanced  
IR@PKUHSC  > 北京大学第二临床医学院  > 期刊论文
学科主题: 临床医学
题名:
Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients
作者: Kush, Debra1; Hu, Da-Yi2; Ye, Ping3; Kim, Hyo-Soo4; Chen, Erluo; Sirah, Waheeda; Sisk, Christine McCrary; Paolini, John F.; Maccubbin, Darbie
关键词: Extended-release niacin ; Flushing ; Laropiprant
刊名: CARDIOLOGY
发表日期: 2009
DOI: 10.1159/000228585
卷: 114, 期:3, 页:192-198
收录类别: SCI
文章类型: Article
WOS标题词: Science & Technology
类目[WOS]: Cardiac & Cardiovascular Systems
研究领域[WOS]: Cardiovascular System & Cardiology
关键词[WOS]: NICOTINIC-ACID ; PRIMARY HYPERCHOLESTEROLEMIA ; CORONARY-DISEASE ; NIACIN NIASPAN ; LONG-TERM ; EFFICACY ; DYSLIPIDEMIA ; TOLERABILITY ; CHOLESTEROL ; LOVASTATIN
英文摘要:

Objective: Niacin is underutilized due to flushing, which occurs in over 90% of niacin-treated patients. Laropiprant (LRPT) reduces flushing associated with niacin. This study compared flushing with a combination tablet of extended-release (ER) niacin (ERN)/LRPT to niacin ER (N-ER; without LRPT) during the first week of therapy among patients in Asia. Methods: Following a 1-week placebo run-in, 332 patients with dyslipidemia from China, Korea and Singapore were randomized to ERN/LRPT 1 g/20 mg, N-ER 1 g (given as Niaspan (R)) or placebo in a 2: 2: 1 ratio for 1 week. Patient-reported flushing severity was assessed using the Global Flushing Severity Score (GFSS; none/mild = 0-3; moderate = 4-6; severe = 7-9; extreme = 10). Results: Compared with N-ER, the ERN/LRPT group experienced significantly less flushing (p < 0.001), as measured by maximum GFSS categorized as none/mild, moderate, severe or extreme. Overall, 23.8% of patients in the ERN/LRPT group and 50.0% in the N-ER group (p < 0.001), versus 12.1% in the placebo group, had moderate or greater flushing (GFSS >= 4). Except for flushing, which occurred more frequently in the N-ER group, ERN/LRPT had a safety/tolerability profile similar to that of N-ER. Conclusion: ERN/LRPT produced significantly less flushing than N-ER during the initiation of therapy and was generally well tolerated in Asian patients with dyslipidemia. Copyright (C) 2009 S. Karger AG, Basel

语种: 英语
项目资助者: Merck &amp ; Co. Inc., Whitehouse Station, N.J., USA
WOS记录号: WOS:000270364900006
Citation statistics:
内容类型: 期刊论文
URI标识: http://ir.bjmu.edu.cn/handle/400002259/55036
Appears in Collections:北京大学第二临床医学院_期刊论文

Files in This Item:

There are no files associated with this item.


作者单位: 1.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
2.Merck & Co Inc, Merck Res Labs, Cardiovasc Dis, Rahway, NJ 07065 USA
3.Chinese Peoples Liberat Army Gen Hosp, Beijing, Peoples R China
4.Seoul Natl Univ Hosp, Seoul 110744, South Korea

Recommended Citation:
Kush, Debra,Hu, Da-Yi,Ye, Ping,et al. Flushing Profile of Extended-Release Niacin/Laropiprant at Initiation of Therapy in Asian Lipid Clinic Patients[J]. CARDIOLOGY,2009,114(3):192-198.
Service
Recommend this item
Sava as my favorate item
Show this item's statistics
Export Endnote File
Google Scholar
Similar articles in Google Scholar
[Kush, Debra]'s Articles
[Hu, Da-Yi]'s Articles
[Ye, Ping]'s Articles
CSDL cross search
Similar articles in CSDL Cross Search
[Kush, Debra]‘s Articles
[Hu, Da-Yi]‘s Articles
[Ye, Ping]‘s Articles
Related Copyright Policies
Null
Social Bookmarking
Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit

Items in IR are protected by copyright, with all rights reserved, unless otherwise indicated.

 

 

Valid XHTML 1.0!
Copyright © 2007-2017  北京大学医学部 - Feedback
Powered by CSpace